MIT Sloan School of Management
Cambridge, Massachusetts 


PharmaGenomics Journal's

Pharmacogenomics is the study of how an individual's genetic inheritance affects the body's response to drugs. The term comes from the words pharmacology and genomics and is thus the intersection of pharmaceuticals and genetics.  Pharmacogenomics holds the promise that drugs might one day be tailor-made for individuals and adapted to each person's own genetic makeup. Environment, diet, age, lifestyle, and state of health all can influence a person's response to medicines, but understanding an individual's genetic makeup is thought to be the key to creating personalized drugs with greater efficacy and safety.  Pharmacogenomics combines traditional pharmaceutical sciences such as biochemistry with annotated knowledge of genes, proteins, and single nucleotide polymorphisms.


Medical Imaging in Drug Discovery, Part II

Molecular imaging is beginning to be applied to pre-clinical drug development efforts, and a number of new companies are poised to serve this market, touting their molecular imaging technologies as specifically aiding drug development.

Industry Watch: Medical Imaging in Drug Discovery, Part I

While economic, scientific and regulatory questions still need to be answered, imaging technologies have the potential to increase efficiencies in many areas of drug research.  This first of a three-part series examines initial applications in clinical trials and industry's growing interest in monitoring biomarkers throughout discovery and development.

The Question of Compliance

The full potential of personalized medicine cannot be realized if patients don't follow their treatment regimens.  The authors address this tissue, using diabetes as an example, and discuss new clinical monitoring and feedback systems that could complement the industy's drug development efforts.

See You in December?

A symposium was held this winter at the Massachusetts Institute of Technology that provides a comprehensive focus on the science and technology, clinical medicine and economic and policy implications of pharmacogenomics.

Getting Personal with Pain

Pain research seems to be ideal for the application of pharmacogenomics, but pharmaceutical companies have invested little research in the area.  The authors discuss opportunities and approaches in the pain management market.

A Public/Private Partnership for Dual-Use Antibiotics

Pharmacogenomics offers potential new approaches to defend against both bacterial resistance and bioterrorism, but the pursuit of new antibiotic medications is not particularly attractive from a business standpoint.  A public/private partnership could provide the structure for the R&D effort.

Getting to Rational Drug Design at Last

The industry now has the research tools to pursue rational drug design successfully, but a new hurdle is being raised: finding a way to generate data and manage our knowledge of disease that maximizes the value of that knowledge.

The Coming Paradigm Shift in Pharmaceuticals

Pharmacogenomics holds the promise of more effective and better-tolerated therapies, which, in turn, mean more efficient use of healthcare resources.  But there are many hurdles on the way to the pharmacy of the future.

The Promise of Protein Microarrays

Despite some formidable technical challenges, protein microarray and other biochip technologies are among the most important tools for the analysis of cell physiology as a set of linked networks.

Integrating the Science and Technology Revolutions

There's no question that technology influences drug development, and that innovation is one of the driving forces behind improved health worldwide.  How will new science and technology change healthcare?  What does the future hold for the pharmaceutical industry?


For more journal articles:


To read articles on this site requires Adobe Acrobat Reader.
Click here for your free copy...
PDF Reader



Copyright 2004 POPI. All rights reserved